YMPHOGEN Adds Receptor’s Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody - Gilde Healthcare

YMPHOGEN Adds Receptor’s Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody

January 29, 2009

COPENHAGEN, Denmark and PALO ALTO, Calif., U.S. –  Symphogen A/S and Receptor BioLogix, Inc ,( Receptor). announced today that Symphogen has acquired the technology and programs of Receptor BioLogix. Symphogen is a leader in developing recombinant polyclonal antibodies, a new class of biopharmaceuticals, and Receptor BioLogix is a pioneer in developing pan-HER ligand traps to treat cancer and other diseases.  Both companies are privately owned.

“Receptor BioLogix’s innovative pan-HER ligand trap technology is an excellent fit with our scientific and strategic focus,”

said Kirsten Drejer, Ph.D., CEO of Symphogen.

“We are  developing novel biologics explicitly designed to address disease complexity, with the goal of achieving better efficacy than single-targeted drugs that fail to account for the complex nature of many diseases.   We expect our established infrastructure and highly relevant expertise in developing complex biologics will facilitate the rapid progress of the pan-HER cancer program, which we believe has breakthrough potential.”

The complex HER (human EGF receptor) family of receptors and growth factor ligands is dysregulated in about half of all solid cancers.  Receptor BioLogix’s pan-HER ligand traps are engineered proteins combining an antibody-like element along with multiple HER receptors.  They are designed to block the diverse ligands that stimulate tumor growth.  A recent scientific publication needs reference confirmed that the company’s pan-HER ligand traps can successfully trap, multiple tumor-promoting HER ligands and achieve a range of anti-tumor effects.  Receptor BioLogix’s pan-HER ligand traps are in pre-clinical development.

“Symphogen brings first-class scientific, drug development and manufacturing expertise to our exciting pan-HER program,”

said Dale R. Pfost, Ph.D., former CEO of Receptor BioLogix.  

“Our team has done an outstanding job of advancing our pan-HER ligand traps in the past months, and we concluded that the advantages of now combining our assets with an organization with an analogous approach and greater resources were compelling—we see strong synergies between the two firms.  We believe our pan-HER ligand traps have the potential to transform the treatment of HER-related cancers and that Symphogen is an ideal company to take them to the next stage.”

Financial details of the transaction were not disclosed.

About Symphogen

Symphogen is the leader in developing recombinant polyclonal antibodies (pAb), a new class of biopharmaceuticals for the treatment of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system. Symphogen is building a proprietary product pipeline within several disease areas, including infectious diseases and cancer.  Symphogen is a private biopharmaceutical company with over 70 employees, based in Copenhagen, Denmark. Refer to www.symphogen.com  for further information on Symphogen.

About Receptor BioLogix

Receptor BioLogix has applied its expertise in human EGF receptor (HER) pathways and receptor-based biologics to develop novel pan-HER ligand traps for cancer and other diseases.  The company’s pan-HER ligand traps are engineered proteins specifically designed to inhibit the compensatory feedback mechanisms that limit the efficacy and durability of many cancer drugs.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022